Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial authorization (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead candidate, PTD802.